Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI) / genitourinary (GU)
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A Phase 1/2a Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A Phase Ib /Randomized Phase III Trial of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab consolidation in patients with minimal residual disease positivity
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 4, 2023
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 4, 2023
Prospective longitudinal bio-specimen collection in patients with early breast cancer patients who receive pre-operative systemic therapy, post-operative adjuvant systemic therapy, and metastatic breast cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 26, 2023
Prognostic Significance of Circulating Tumor Cells in Prostate Cancer: A Pilot Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 26, 2023
Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 Administered in Patients With Relapsed/Refractory AML or Newly Diagnosed High-Risk AML
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 12, 2023
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 12, 2023